Skip to content

Search everything Close Menu

Close

Main menu

* Company

* Company overview

* Stories

* History

* Responsibility

* Responsibility overview

* Philanthropy

* Leadership

* Leadership overview * Board of directors

* Executive team

* Culture & values

* Culture & values overview * Code of conduct & compliance * Diversity & inclusion * Policies & positions * Business development & licensing

* Suppliers

* Suppliers overview * Supplier registration * Research & products * Research & products overview

* COVID-19

* Areas of focus

* Oncology

* Vaccines

* Infectious diseases * Cardio-metabolic disorders

* Pipeline

* Discovery & development

* Clinical trials

* Clinical trials overview

* Find a trial

* Products list

* Safety data sheets (SDS)

* Product patents

* Merck authorized distributors

* Patients

* Patients overview

* Patient support programs

* Patient resources

* Patient & treatment education

* Careers

* Careers

* Search jobs

* Our divisions

* Research & development * Manufacturing & supply

* Human Health

* Animal Health

* Global support functions

* Veterans

* Student opportunities * Re-invent returnship * Compensation & benefits

* How we hire

* MSD Careers

* Events

* Talent community

* Investors

* Investors overview * Events & presentations * Financial information * Financial information overview

* SEC filings

* Stock information

* Investor resources * Investor resources overview * Request for information

* Media

* Media overview

* News releases

* Company statements * Media contact & library * Media contact & library overview * Company fact sheet

Responsibility

YOUR QUESTIONS ANSWERED: HOW MERCK IS RESPONDING TO THE COVID-19

PANDEMIC

Learn more

Contact us

Worldwide

Countries outside of the United States and Canada. WHAT CAN WE HELP YOU FIND?

Search for:

MEDIA

Our latest news, announcements and multimedia resources

VIDEO COMING SOON

LATEST NEWS

News releasesCompany statements

June 3, 2021

Merck Announces Completion of Organon & Co. Spinoff

June 1, 2021

Merck and Sanofi’s First and Only Six-in-One Pediatric Combination Vaccine Now Available in the United States

May 25, 2021

Merck Announces Third-Quarter 2021 Dividend

May 24, 2021

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as First-Line Treatment for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) Adenocarcinoma

May 20, 2021

Merck Announces Positive Topline Results from PNEU-DIRECTION (V114-027) and PNEU-PLAN (V114-024) Phase 3 Pediatric Studies for V114, Merck’s Investigational 15-valent Pneumococcal Conjugate

Vaccine

May 17, 2021

Gabrielle Union-Wade Joins ‘Don’t Skip’ Campaign to Encourage Doctor Well-Visits and Recommended Vaccinations

View all

April 29, 2021

Merck Provides Update on FDA’s Oncologic Drugs Advisory Committee (ODAC) Meetings on April 28-29, 2021

March 11, 2021

FDA’s Oncologic Drugs Advisory Committee to Discuss Three Indications for KEYTRUDA® (pembrolizumab) During Meetings Focused on Accelerated Approvals

February 9, 2021

Merck Announces Outcome of Oncologic Drugs Advisory Committee (ODAC) for KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

February 4, 2021

Merck Statement on Ivermectin use During the COVID-19 Pandemic

January 27, 2021

Merck to Construct New Facility in the United States to Expand Manufacturing Capacity for TICE® BCG

January 13, 2021

Merck Confirms Agreement with UNICEF to Establish the World’s First Global Ebola Vaccine Stockpile with ERVEBO® (Ebola Zaire Vaccine,

Live)

View all

MEDIA RESOURCES

NEWS RELEASES

Read our latest news releases.

COMPANY STATEMENTS

Read our latest company statements.

MEDIA LIBRARY

Access videos, logos, photos and infographics. MEDIA CONTACT DETAILS

GENERAL

General media inquiries

+1 908-740-5633

mediarelations@merck.com

PATRICK RYAN

Corporate media relations

+1 973-275-7075

patrick.ryan4@merck.com

JOHN CUMMINS

Policy media relations

+1 202-508-4567

john.cummins2@merck.com GET TO KNOW US THROUGH OUR STORIES Everything we do, in and out of the laboratory, is based on our deep appreciation for life. Get a glimpse of what it's like on the inside through our stories.

Read on

WE ARE DRIVEN BY A SHARED PURPOSE TO INVENT FOR LIFE Our mission is to discover, develop and provide innovative products and services that save and improve lives around the world. Learn more about our company

INVESTOR RELATIONS

Find our latest financials, events & presentations, news, stock information and investor contacts. Visit investor relations

COMPANY FACT SHEET

Access company information including stock ticker, official company names, description, and more. See company fact sheet SIGN UP FOR EMAIL ALERTS Receive company news, updates and other information Unsubscribe from email alerts CONNECT WITH US ON SOCIAL For patients and health care professionals

* MerckHelps

Merck Patient Assistance Program provides certain Merck medicines and adult vaccines for free to qualified patients * Merck Access Program Information about insurance coverage and financial assistance options for eligible patients

* Clinical trials

Learn about our clinical trials and find available studies

* Merck Manuals

Medical information source covering thousands of topics in all fields

of medicine

Corporate responsibility * Corporate Responsibility Report Reporting on our commitment to society, people and communities around

the world

* Merck for Mothers

An initiative to create a world where no woman has to die giving life

About Merck

* Merck Animal Health The global animal health business unit of Merck * Forward-looking statement

* Cookie policy

* Cookie Preferences

* Privacy

* Transparency disclosure

* Terms of use

* Sitemap

Copyright © 2009-2021 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved. FORWARD-LOOKING STATEMENT OF MERCK & CO., INC., KENILWORTH, N.J., USA This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov ).

NO DUTY TO UPDATE

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the

presentation date.

Decline Accept

YOU ARE LEAVING MERCK.COM

Cancel Continue

WELCOME TO MERCK.COM By continuing, you will be directed to a site intended only for residents of the United States and Canada. We are called MSD everywhere, except in the United States and Canada where we are known as Merck & Co Inc, Kenilworth, NJ USA

Continue

PRIVACY PREFERENCE CENTER

YOUR PRIVACY

YOUR PRIVACY

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer. More information

*

STRICTLY NECESSARY COOKIES STRICTLY NECESSARY COOKIES

Always Active

Strictly Necessary Cookies These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Cookies Details‎

*

FUNCTIONAL COOKIES

FUNCTIONAL COOKIES

Always Active

Functional Cookies

These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. The cookies ensure that these services function properly.

Cookies Details‎

*

PERFORMANCE COOKIES

PERFORMANCE COOKIES

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site.    All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Cookies Details‎

*

TARGETING COOKIES

TARGETING COOKIES

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites.    They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Cookies Details‎

*

SOCIAL MEDIA COOKIES SOCIAL MEDIA COOKIES Social Media Cookies These cookies are set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your browser across other sites and building up a profile of your interests. This may impact the content and messages you see on other websites you visit.    If you do not allow these cookies you may not be able to use or see these

sharing tools.

Cookies Details‎

Back Button

ADVERTISING COOKIES

Filter Button

Consent Leg.Interest

Select All Vendors

Select All Vendors

Select All Hosts

Select All

*

REPLACE-WITH-DYANMIC-HOST-ID

33ACROSS

33ACROSS

View Third Party Cookies

*

Name

cookie name

*

REPLACE-WITH-DYANMIC-VENDOR-ID

33ACROSS

3 Purposes

View Privacy Notice

33ACROSS

3 Purposes

View Privacy Notice

REPLACE-WITH-DYANMIC-VENDOR-ID

Consent Purposes

Location Based Ads

Consent Allowed

Legitimate Interest Purposes

Personalize

Require Opt-Out

Special Purposes

Location Based Ads

Features

Location Based Ads

Special Features

Location Based Ads

Clear Filters

Information storage and accessApply Confirm My Choices Accept All Cookies THIS SITE USES COOKIES AND YOUR PRIVACY CHOICE IS IMPORTANT TO US We suggest you choose _Customize My Settings_ to make your individualized choices. _Accept All Cookies_ means that you are choosing to accept third-party Cookies and that you understand this choice. See our Privacy Policy Customize My Settings Accept All Cookies